AXIM BIOTECHNOLOGIES INC - AXIM STOCK NEWS

AXIM Biotechnologies, Inc. (OTCQB: AXIM) has completed the optimization of a rapid diagnostic test for the quantitative measurement of Ocular Immunoglobulin E (IgE), a biomarker for ocular allergies. This FDA-cleared test, which previously took 15 minutes, has been miniaturized to deliver results in just 7 minutes. With approximately 40% of the population experiencing allergic conjunctivitis, this enhanced test allows primary eye care providers to double their patient testing capacity, potentially leading to increased profitability for AXIM.

AXIM Biotechnologies has developed a new tear sample collector system and filed a provisional patent with the U.S. Patent and Trademark Office. This system improves patient experience and is easier for untrained personnel to use, addressing the challenges of current collectors. With Dry Eye Disease affecting approximately 6.8% of the U.S. population, the company plans to integrate this system into its Point-of-Care Biomarker Tests for faster diagnosis. CEO John Huemoeller expressed optimism about the system's potential impact on the ophthalmology field.

AXIM Biotechnologies (OTCQB: AXIM) has developed a rapid quantitative tear test for Lacritin, a protein involved in tearing, targeting Dry Eye Disease (DED). Approximately 6.8% of the U.S. population experiences DED, with many undiagnosed. Lacritin promotes tear secretion and cell survival, important in treating DED. The CEO noted this test could enhance diagnosis and treatment, contributing to shareholder value. AXIM also has FDA-cleared tests for lactoferrin and IgE, aiming for a comprehensive DED diagnostic program.

AXIM Biotechnologies is strategically focusing on the commercialization of its FDA-cleared Dry Eye Disease (DED) diagnostic system. The company aims to address the underserved DED diagnosis market with its patent-pending tear collection method and approved tests, leveraging a strong DED management team. Supply agreements are secured to meet the demand for DED readers and test strips, promising significant revenue potential. Furthermore, AXIM plans to submit a Phase II grant to advance its oncological program, emphasizing the need for positive cash flow through its DED initiatives.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) announced a breakthrough in the diagnosis of Dry Eye Disease (DED) with a new rapid quantitative tear test for MMP-9, an inflammatory biomarker. This advancement addresses the common issue of under-diagnosis in DED, which has inconsistent symptom and sign correlations. The new test provides more accurate measurements of MMP-9 levels, enhancing early detection and treatment outcomes for patients. CEO John Huemoeller highlighted the significant market potential, noting that nearly half of U.S. adults may experience dry eye symptoms.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) has shifted its COVID-19 Neutralizing Antibody Test to a For Research Use Only (RUO) designation. This change aims to provide researchers a tool for studying COVID-19, without diagnostic applications. The Company has also parted ways with Empowered Diagnostics following an FDA recall of related products. AXIM's test, initially developed for emergency use, will now assist in various research areas, including vaccine efficacy and adaptive immune responses. The RUO tests include both quantitative and semi-quantitative options.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) has announced significant advancements in its initiative for diagnosing Dry Eye Disease (DED). The company signed a supply agreement with IUL for iPeak readers, which will enhance testing for lactoferrin levels. Additionally, it has developed a patented Tear Collector System aimed at improving sample collection. Veteran lab testing executive Barry Craig has joined to oversee the testing initiative, ensuring compliance and management of the field studies. AXIM aims to lead the DED diagnostic market with its innovative approaches.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) announced the CDC’s recognition of a study they sponsored on neutralizing antibodies, highlighting that 25% of two-dose RNA vaccine recipients are 'vaccine poor responders.' A third dose significantly improves antibody levels. Dr. Douglas Lake noted the importance of awareness regarding vaccine effectiveness. The press release emphasizes AXIM's commitment to understanding antibody levels and their impact, alongside ongoing efforts in COVID-19 diagnostics. The study was co-authored by AXIM’s Chief Scientific Officer, further cementing the company's research credibility.

AXIM Biotechnologies is currently under FDA review for its first rapid test to measure neutralizing antibodies for COVID-19. The FDA has prioritized emergency use authorization for various diagnostic tests, enhancing the company's testing efforts. AXIM has developed three types of neutralizing antibody tests, demonstrating over 90% sensitivity and 100% specificity in trials. The manufacturing partner has filed for Emergency Use Authorization in Canada and the EU. This advancement aligns with AXIM’s strategy to improve COVID-19 diagnostics significantly.